Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Preliminary data suggests mixing Covid-19 vaccine increases reactogenicity

Research, from Com-COV study comparing mixed dosing schedules of Pfizer / Oxford-AstraZeneca vaccines, shows increase in the frequency of mild-moderate symptoms in those receiving either mixed dosing schedule. Adverse reactions were short-lived, with no other safety concerns. Impact of mixed schedules on immunogenicity unknown as yet, with data to follow from this study.

Childhood abdominal pain may be linked to disordered eating in teenagers

New research shows that people who suffer from recurrent abdominal pain in childhood may be more likely to have disordered eating as teenagers.

COVID-19 vaccine messaging that focuses on personal benefits is most effective with those who are hesitant

For the one in ten who say they won’t take a COVID-19 vaccine, messaging that focuses on personal rather than collective benefits is more effective.

Fifth of new Academy of Medical Sciences Fellows from Oxford University

The Academy of Medical Sciences has elected 11 University of Oxford biomedical and health scientists to its fellowship.

Promising malaria vaccine enters final stage of clinical testing in West Africa

R21/Matrix-M becomes the second malaria vaccine candidate ever to start a phase III licensure trial. This builds on the recent finding of high level efficacy of this vaccine in a phase IIb trial in children in Burkina Faso, published today in The Lancet. The first phase III trial doses were administered by the team at the Malaria Research and Training Centre, Bamako, Mali, one of five trial sites across West and East Africa. The malaria vaccine was designed at the Jenner Institute, University of Oxford, who have partnered with the Serum Institute of India for commercial development.

Oxford Researchers elected to Royal Society

Six scientists from the University of Oxford have joined the Royal Society as Fellows.

Multi-partner 'OpenMind' consortium to develop technology for new generation of neurostimulation devices

Investigators at the University of Oxford, University of California San Francisco (UCSF), Brown University and the Mayo Clinic have joined forces to develop open-source technology platforms for a new generation of neurostimulation devices that not only provide stimulation to the brain but also sense, record, and stream brain activity.

Policies for COVID-19 elimination, not mitigation, best for health, economy and civil liberties

Countries which aimed to eliminate COVID-19 registered fewer deaths, better economic performance and fewer restrictions and lockdowns, according to an article in The Lancet.

Rapid evolution and host immunity drive the rise and fall of antibiotic resistance during acute infection

Antibiotic resistance poses a serious threat to human health. Resistant infections now cause more than 750,000 deaths per year and are predicted to increase to 10 million deaths per year by 2050. It is known that treating patients with antibiotics is associated with the emergence of resistance - and worse outcomes for patients. But how resistance emerges during infections remains poorly understood.

Research uncovers high risk to pregnant women from COVID-19

A study of more than 2,100 pregnant women across 18 countries worldwide has revealed that COVID-19 is associated with a higher risk of severe maternal and newborn complications than previously recognised.

Significant reductions in COVID-19 infections found after single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine

COVID-19 infections fell significantly – by 65% percent - after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study.

Malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal

- High-level vaccine efficacy of 77% in African children achieve WHO-specified efficacy goal of 75% - Vaccine, trialled in 450 children, shows favourable safety profile and was well-tolerated - Vaccine candidate, R21/Matrix-M, has excellent potential for large-scale manufacturing and low- cost supply

Oxford University and Prenetics announce landmark collaboration to scale rapid testing tech globally

Today, the University of Oxford, Prenetics Limited, a global leader in diagnostics and genetic testing, and Oxford Suzhou Centre for Advanced Research (OSCAR) have signed collaboration agreements to further develop the award-winning OxLAMPTM technology, a rapid, molecular testing technology for infectious diseases.

Human challenge trial launches to study immune response to COVID-19

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Can viruses hijack their hosts' circadian rhythms?

26 Mar 2021 By Professor Jane McKeating, Nuffield Department of Medicine Our lives are so often dictated by time - it seems like we are not the only ones.

Hypoxia drugs join the fight against COVID-19

13 Apr 2021 By Professor Jane McKeating, Nuffield Department of Clinical Medicine Oxygen is essential to all life forms, even viruses.

Alternating vaccines trial expands to include two additional vaccines

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the UK’s PRINCIPLE trial in 1,779 participants.

The passing of His Royal Highness The Prince Philip, Duke of Edinburgh

The University of Oxford is deeply saddened to learn of the death of His Royal Highness, the Duke of Edinburgh. The University was honoured by a close relationship with the Duke, who visited on many occasions over the last six decades and held several honorary positions.

Load More